NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has agreed to acquire German diagnostics firm Brahms for €330 million ($471 million) in a deal that will complement its immunoassay test portfolio and expand its reagent manufacturing capabilities in Europe.

Brahms, based in Henningsdorf, Germany, makes tests based on biomarkers for sepsis, cardiovascular, and pulmonary diseases, as well as intensive care treatments and prenatal screening products. The firm has around 400 employees in 65 countries worldwide and had 2008 annual revenues of approximately $105 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.